← Back to Search

Monoclonal Antibodies

Cryo-activation for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Moishe Liberman, MD PhD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years)
Awards & highlights

Study Summary

This trial is testing whether adding cryo-activation to ICB in advanced NSCLC will help the ICB work better.

Eligible Conditions
  • Non-small Cell Lung Cancer Metastatic
  • Cryotherapy Effect

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Best overall response rate (BORR; change from baseline)
Secondary outcome measures
Incidence of treatment-related adverse events (Safety and tolerability)
Overall survival (OS)
Progression-free survival (PFS)

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Pneumothorax
5%
Malnutrition, Hypercalcemia and Weakness
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cryo-activation and anti-PD-1 monotherapy combinationExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cryo-activation
2021
N/A
~20
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
370 Previous Clinical Trials
129,854 Total Patients Enrolled
Moishe Liberman, MD PhDPrincipal InvestigatorCHUM
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top